参考文献

1.Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015. CA Cancer J Clin，2016，66：115-132.

2.Herbst RS，Bajorin DF，Bleiberg H，et al. Clinical Cancer Advances 2005：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology. J Clin Oncol，2006，24：190-205.

3.Ozols RF，Herbst RS，Colson YL，et al. Clinical Cancer Advances 2006：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology. J Clin Oncol，2006，25（1）：146-162.

4.Gralow J，Ozols RF，Bajorin DF，et al. Clinical Cancer Advances 2007：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology. J Clin Oncol，2008，26：313-325.

5.Petrelli NJ，Winer EP，Brahmer J，et al. Clinical Cancer Advances 2009：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology. J Clin Oncol，2009，27：6052-6069.

6.Winer E，Gralow J，Diller L，et al. Clinical Cancer Advances 2008：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology. J Clin Oncol，2009，27：812-826.

7.Krismg，Benowitz SI，Adams S，et al. Clinical Cancer Advances 2010：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2010，28：5327-5347.

8.Vogelzang NJ，Benowitz SI，Adams S，et al. Clinical Cancer Advances 2011：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Onco，2012，30：88-109.

9.Roth BJ，Krilov L，Adams S，et al. Clinical Cancer Advances 2012：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2013，31：131-161.

10.Patel JD，Krilov L，Adams S，et al. Clinical Cancer Advances 2013：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2014，32：129-160.

11.Masters GA，Krilov L，Bailey HH，et al. Clinical cancer advances 2015：Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol，2015，33：786-809.

12.Dizon DS，Krilov L，Cohen E，et al. Clinical Cancer Advances 2016：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2016，34：987-1011.

13.Yang JC，Wu YL，Schuler M，et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma （LUX-Lung 3 and LUX-Lung 6）：analysis of overall survival data from two randomised，phase 3 trials. Lancet Oncol，2015，16：141-151.

14.Yang JC，Sequist LV，Geater SL，et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations：a combined post-hoc analysis of LUX-Lung 2，LUX-Lung 3，and LUX-Lung 6. Lancet Oncol，2015，16：830-838.

15.Zhou C，Wu YL，Chen G，et al. BEYOND：A Randomized，Double-Blind，Placebo-Controlled，Multicenter，Phase Ⅲ Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol，2015，33：2197-2204.

16.Zhou Q，Cheng Y，Yang JJ，et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR （CTONG0806）：a multicenter randomized trial.Ann Oncol，2014，25：2385-2391.

17.Deng Y，Chi P，Lan P，et al. A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer （FOWARC study）：Preliminary results. J Clin Oncol，2015，33：（suppl；abstr 3500）.

18.Li J，Qin S，Xu R，et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer （CONCUR）：a randomised，double-blind，placebocontrolled，phase 3 trial. Lancet Oncol，2015，16：619-629.

19.Xu R-H，Shen L，Wang K，et al. A randomized，double-blind，parallel-group，placebo-controlled，multicenter，phase Ⅱ clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. J Clin Oncol，2015，33：（suppl 3；abstr 513）.

20.Xu J，Xia J，Gu Y，et al. Effect of preoperative hepatic and regional arterial chemotherapy on metachronous liver metastasis after curative colorectal cancer resection：A prospective，multicenter，randomized controlled trial. J Clin Oncol，2015，33：（suppl 3；abstr 511）.

21.Li J，Qin S，Xu J，et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer：results from a randomized，placebo-controlled，parallel-arm，phase Ⅱ trial. J Clin Oncol，2013，31：3219-3225.

22.Wang J，Xu R，Li J，et al. Randomized multicenter phase Ⅲ study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer，2016，19：234-244.

23.Hu XC，Zhang J，Xu BH，et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer （CBCSG006）：a randomised，open-label，multicentre，phase 3 trial. Lancet Oncol，2015，16：436-446.

24.Wei WQ，Chen ZF，He YT，et al. Long-Term Follow-Up of a Community Assignment，One-Time Endoscopic Screening Study of Esophageal Cancer in China. J Clin Oncol，2015，33：1951-1957.

25.Huang H，Li X，Zhu J，et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy：a randomized clinical trial. JAMA，2014，312：2521-2530.

26.Shi Y，Dong M，Hong X，et al. Results from a multicenter，open-label，pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol，2015，26：1766-1771.

27.Xu X，Lu D，Ling Q，et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut，2015.

28.Ren Z，Zhu K，Kang H，et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol，2015，33：894-900.